Fate Therapeutics (NASDAQ:FATE) Issues Earnings Results, Beats Estimates By $0.01 EPS

Posted by Stanley Muller on Aug 14th, 2026

Fate Therapeutics (NASDAQ:FATE – Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01, FiscalAI reports. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $1.37 million. Fate Therapeutics had a negative net margin of 2,056.79% and a negative return on equity of 58.89%.

Fate Therapeutics Stock Down 7.4%

FATE stock opened at $2.52 on Friday. Fate Therapeutics has a 52 week low of $0.93 and a 52 week high of $3.23. The firm has a 50-day simple moving average of $2.49 and a 200-day simple moving average of $1.86. The stock has a market capitalization of $293.73 million, a P/E ratio of -2.31 and a beta of 2.52.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on FATE. Jefferies Financial Group set a $4.00 price objective on Fate Therapeutics in a report on Tuesday, May 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fate Therapeutics in a research report on Friday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research report on Monday, June 8th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.00.

Check Out Our Latest Research Report on Fate Therapeutics

Insider Transactions at Fate Therapeutics

In other Fate Therapeutics news, insider Cindy Tahl sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $1.88, for a total transaction of $48,109.20. Following the completion of the sale, the insider directly owned 628,155 shares in the company, valued at approximately $1,180,931.40. The trade was a 3.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 4.74% of the company’s stock.

Institutional Trading of Fate Therapeutics

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Fate Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 8,798,491 shares of the biopharmaceutical company’s stock valued at $11,086,000 after purchasing an additional 31,727 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Fate Therapeutics by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,429,167 shares of the biopharmaceutical company’s stock worth $2,721,000 after buying an additional 159,558 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Fate Therapeutics by 87.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,360,881 shares of the biopharmaceutical company’s stock worth $2,320,000 after buying an additional 1,098,366 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Fate Therapeutics by 2.7% in the fourth quarter. AQR Capital Management LLC now owns 1,162,005 shares of the biopharmaceutical company’s stock valued at $1,142,000 after buying an additional 30,591 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Fate Therapeutics by 9.6% in the third quarter. Millennium Management LLC now owns 963,871 shares of the biopharmaceutical company’s stock valued at $1,214,000 after buying an additional 84,183 shares during the last quarter. 97.54% of the stock is currently owned by hedge funds and other institutional investors.

Fate Therapeutics Company Profile

(Get Free Report)

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.